Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has been given a consensus rating of "Hold" by the twenty brokerages that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $71.24.
INSP has been the topic of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Inspire Medical Systems from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 3rd. Robert W. Baird boosted their price target on Inspire Medical Systems from $73.00 to $77.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 3rd. UBS Group initiated coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They issued a "sell" rating and a $39.00 price target for the company. Barclays lowered their price objective on shares of Inspire Medical Systems from $65.00 to $62.00 and set an "underweight" rating for the company in a research report on Tuesday, November 3rd. Finally, Weiss Ratings downgraded shares of Inspire Medical Systems from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, November 12th.
View Our Latest Stock Analysis on Inspire Medical Systems
Hedge Funds Weigh In On Inspire Medical Systems
Several institutional investors and hedge funds have recently made changes to their positions in INSP. BlackRock Inc. bought a new stake in Inspire Medical Systems during the second quarter valued at $211,341,000. William Blair Investment Management LLC bought a new position in shares of Inspire Medical Systems during the third quarter valued at approximately $44,362,000. Goldman Sachs Group Inc. increased its position in shares of Inspire Medical Systems by 77.7% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,147,831 shares of the company's stock valued at $79,614,000 after purchasing an additional 501,973 shares during the period. ADAR1 Capital Management LLC raised its stake in shares of Inspire Medical Systems by 2,601.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company's stock worth $20,900,000 after buying an additional 390,197 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Inspire Medical Systems by 66.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company's stock valued at $38,561,000 after acquiring an additional 344,221 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.
Inspire Medical Systems Stock Performance
Inspire Medical Systems stock opened at $56.51 on Friday. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03. The firm has a 50 day moving average price of $68.41 and a 200 day moving average price of $57.31. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 4.25 and a beta of 0.67.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. Inspire Medical Systems had a net margin of 11.43% and a return on equity of 7.32%. The company had revenue of $206.69 million for the quarter, compared to the consensus estimate of $204.31 million. During the same quarter last year, the firm posted $0.38 earnings per share. Inspire Medical Systems's revenue was down 7.9% on a year-over-year basis. Sell-side analysts predict that Inspire Medical Systems will post 1.29 EPS for the current year.
Inspire Medical Systems Company Profile
(
Get Free Report)
Inspire Medical Systems is a medical technology company focused on treatments for obstructive sleep apnea, a condition in which breathing repeatedly stops or becomes restricted during sleep. Founded in 2007 and based in Minnesota, the company develops implantable devices intended for certain patients who cannot use or benefit from conventional positive airway pressure therapy. Its primary product, the Inspire Upper Airway Stimulation system, uses an implanted device to monitor breathing and deliver mild stimulation to the hypoglossal nerve, helping keep the airway open during sleep.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.